Brief: Maxcyte Signs Strategic Platform License
16/09/2024 07:37
Sept 16 (Reuters) - MaxCyte Inc MXCT.O :
* SIGNING OF STRATEGIC PLATFORM LICENSE
* SIGNS STRATEGIC LICENSE WITH KAMAU THERAPEUTICS
Source text for Eikon: ID:nRSP2334Ea
Further company coverage: MXCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview